The nongovernmental organizations argued that patents for this CAR-T should never have been granted in the first place because the underlying technology is not novel.
Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.
Patients with newly diagnosed AML who are ineligible for intensive chemotherapy may benefit from a 10-day course of decitabine with venetoclax.
Regardless of genotype, venetoclax with a hypomethylating agent yields strong response and survival outcomes among patients with treatment-naive or R/R AML.
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who had an L265P MYD88 mutation were uncommon and had distinct features.
Risk-adapted dosing of bendamustine and rituximab may be beneficial and tolerable for elderly patients with CLL, a retrospective study found.
Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments.
Clinical trial results indicate that adolescent patients with acute lymphoblastic leukemia have poorer outcomes than younger patients do.
The approval was based on data from the multicenter, randomized, double-blind, placebo-controlled, phase 3 QUAZAR study.
Prior treatment with at least 1 novel agent did not affect allogeneic transplant outcomes among patients with CLL.
Race and ethnicity was a factor in risk for pancreatitis among children with ALL, as was age and presence of obesity and hyperglycemia.
Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.
Young patients with newly diagnosed T-cell acute lymphoblastic leukemia showed favorable outcomes with nelarabine added to a treatment regimen.
Investigators aimed to determine the prognostic value of WT1 expression among patients with AML who were in earlier stages of treatment.
In this study, a cohort of patients with newly diagnosed CLL was followed to identify the incidence of SCC skin cancer and its associated risk factors in this population.
As thromboembolism is a common side effect of ALL treatment, investigators assessed whether its occurrence in ALL and in the general adult population have a shared genetic basis.
Even after treatment with hypomethylating agents, older patients with AML still lack positive prognoses but azacitidine with venetoclax shows promise.
Compared with 1970s, rate of subsequent malignant neoplasms lower with standard-risk 1990s-like therapy.
Researchers assessed the efficacy and safety of sorafenib maintenance among patients with FLT3-ITD AML who underwent allogeneic HSCT.
These study findings show the risk and incidence of serious bacterial infection and its effect on mortality for patients with CLL.
Selinexor yields responses in patients with MDS or oligoblastic AML refractory to hypomethylating agents, with manageable adverse events.
Immunotherapy is changing the treatment paradigm for pediatric patients with relapsed acute lymphoblastic leukemia.
The implementation of risk-stratified therapy appears to have reduced late morbidity and mortality among survivors of pediatric acute lymphoblastic leukemia.
Combined with chemotherapy, venetoclax appears to be effective for treating AML among fit elderly patients.
Estimated 10-year cumulative incidence high for subsequent endocrine disease, cardiac disease.
Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.
The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.
Among patients with FLT3-internal tandem repeats, sorafenib maintenance therapy reduces the risk of relapse and death after allo-HSCT.
Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.
Researchers found that identifying and treating acute odontogenic disease before induction chemotherapy prevented infectious dental emergencies in AML patients.
Researchers studied the pros and cons of transplantation from different donor sources to enhance overall outcomes of allo-HSCT in adults with T-cell malignancies.
Some tyrosine kinase inhibitors may cause a hyperinflammatory response.
Risk-adapted therapy effectively prevents fungal infections and reduces neurotoxicity in children with leukemia.
Data from Spain add to the knowledge of Richter syndrome.
Combined ofatumumab and hyper-CVAD is a safe and active treatment for adult patients with (Ph)-negative, CD20-positive B-cell ALL.
The management of CLL, including delays in work-up and treatment, and modifications to clinical trials, have been implemented across Italy in response to the COVID-19 pandemic.
Helsinn and MEI Pharma have discontinued a phase 3 study evaluating pracinostat, in combination with azacitidine, for frontline treatment of older patients with acute myeloid leukemia.
At primary analysis, 40% of patients assigned to the venetoclax arm vs 31% of those assigned to placebo were alive.
Although numerous clinical studies have aimed to treat AML, most results have been disappointing, according to authors of a publication in Blood.
The current state of AML treatment and remaining needs are discussed in an interview with Courtney D. DiNardo, MD, MSCE and Ghayas C. Issa, MD.
Greater intake of foods rich in antioxidants tied to lower rates of infection, mucositis during treatment.
Patients with chronic lymphocytic leukemia who are treated with ibrutinib may have a higher incidence of atrial fibrillation than previously thought.
Patients with B-cell ALL who are treated with CAR T-cell therapy and allo-HSCT may have better outcomes than those treated only with CAR T-cell therapy.
For patients with AML, high immunoglobulin expression is linked to monocytic differentiation, dysplasia, and poorer prognosis.
In this patient case, significant neurological adverse effects associated with nelarabine were noted at 30 days following initiation of therapy.
A study compared the effects of intrathecal triple therapy to intrathecal methotrexate on disease-free survival among patients with B-ALL.
The FDA has expanded the approval of Mylotarg (gemtuzumab ozogamicin; Pfizer) to include treatment of patients aged 1 month and older with newly-diagnosed CD33-positive acute myeloid leukemia.
Among adult patients with newly diagnosed AML, the presence of an FLT3-ITD mutation with an insertion site in the beta1-sheet was associated shorter survival.
In this study, obinutuzumab, ibrutinib, and venoclax were administered as first-line therapy in patients with CLL characterized by del(17p) and/or TP53 mutation.
The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.
In an updated analysis, venetoclax plus low-dose cytarabine improved OS compared with placebo among patients with untreated AML who were ineligible for intense chemotherapy.